Age ≥ 65 years (HR = 2.53, CI95% 1.83–3.51, p < 0.001); a history of prior cancer (HR = 2.36, CI95% 1.35–4.1, p = 0.003); a higher beta-2 microglobulin (B2M) at diagnosis (HR = 1.48, CI95% 1.01–2.18, p = 0.04); and concomitant type 2 diabetes mellitus (T2DM) (HR = 1.82, CI95% 1.21–2.72, p = 0.004) were all associated with a shorter time to SPM detection. This evidence concerns the gene B2M and cancer.